Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to determine the potential ability of intranasal insulin to prevent post-operative cognitive decline and post-operative delirium in an elderly cardiac surgery population.


Clinical Trial Description

Nearly half of all intensive care unit (ICU) admissions consist of adults > 65 years old, an age group that is at high risk for developing cognitive decline and delirium in the ICU. Over 50% and 70% of critically ill cardiac surgery patients develop post-operative delirium (POD) and post-operative cognitive decline (POCD), respectively. These two forms of acute cognitive dysfunction are associated with increased mortality and poor functional recovery. While distinct conditions, POD has been associated with the subsequent development of POCD, suggesting a mechanistic link. No proven pharmacologic treatments targeting the prevention of both POD and POCD in elderly patients exist to date. Recent data suggest that insulin administered into the central nervous system via intranasal delivery improves cognitive function in elderly patients with Alzheimer's disease and mild cognitive impairment. However, its utility in preventing POD and POCD in elderly critically ill patients has not been investigated. The hypothesis of this study is that intranasal insulin can prevent POD and POCD in elderly critically ill patients admitted to the intensive care unit after undergoing cardiac surgery. To test this hypothesis, this randomized, placebo-controlled, double-blinded Phase II study will enroll 60 patients >= 65 years old undergoing elective coronary artery bypass graft and/or valve surgery requiring cardiopulmonary bypass, and will treat them with either 40 IU of aspart insulin or placebo intranasally before surgery and then four times a day for 7 days or until hospital discharge (whichever occurs first). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01561378
Study type Interventional
Source Albert Einstein College of Medicine
Contact
Status Completed
Phase Phase 2
Start date August 2012
Completion date October 2014

See also
  Status Clinical Trial Phase
Recruiting NCT06028126 - Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial N/A
Not yet recruiting NCT05877326 - Anaesthetic Depth and Short Term Delirium Post Cardiac Surgery Intervention N/A
Terminated NCT00991328 - Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery Phase 3
Active, not recruiting NCT03785158 - MIND After Surgery N/A
Recruiting NCT06236854 - Neuroimaging Risk of Postoperative Delirium
Completed NCT00250237 - Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery Phase 3
Completed NCT03953313 - Risk Communication About Post-operative Delirium (POD) and Post-operative Cognitive Dysfunction (POCD)
Recruiting NCT05887076 - Postoperative Delirium After Kidney Transplantation
Recruiting NCT05777187 - Mitigation of Postoperative Delirium in High-Risk Patients N/A
Recruiting NCT05688449 - Effect of Epidural Analgesia on Burst Suppression Phase 4
Completed NCT00791648 - Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery N/A
Completed NCT03132168 - Postoperative Delirium in Patients Undergoing Radical Cystectomy N/A
Completed NCT02692300 - EEG Guidance of Anesthesia (ENGAGES-CANADA) N/A
Completed NCT02325154 - Cerebral Oxygenation in Total Hip Arthroplasty Patients N/A
Active, not recruiting NCT01993992 - Parental Anxiety and Its Relationship With Pediatric Patients' Post-operative Responses N/A
Completed NCT00865202 - A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium Phase 3
Completed NCT05159648 - A Study to Evaluate ICU Simulation Experience in the Cardiothoracic Surgical Population to Reduce Post-operative Delirium
Recruiting NCT06036095 - Total Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study Phase 4
Completed NCT03053869 - Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free) Phase 1